Regarding pancreatic cancer, Olaparib is the only PARP inhibitor that has been FDA-approved for usage in patients with pancreatic cancers with BRCA1 or BRCA2 mutations. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.